AUA 2022: Implementation of Germline Testing in Prostate Cancer
AUA 2022 implementation of germline testing in prostate cancer, role of germline testing in prostate cancer and clinical implications,
AUA 2022 implementation of germline testing in prostate cancer, role of germline testing in prostate cancer and clinical implications,
AUA 2024, bladder cancer, Blue Light Cystoscopy, White Light Cystoscopy, Blue Light Cystoscopy Versus White Light Cystoscopy for the Detection of Bladder Cancer Using Modern…
AUA 2024 comparison of mitomycin C vs BCG treatment, non-muscle invasive bladder cancer, International Bladder Cancer Group (IBCG), Kaplan-Meier analysis.
Rashid Sayyid and Zach Klaassen discuss the AUA’s updated guidelines for managing lower urinary tract symptoms due to BPH, with a focus on medical therapy.…
AUA 2024, photodynamic diagnosis (PDD), Photodynamic Diagnosis-Guided Biopsy,Bladder Mapping Biopsy, BCG therapy for bladder cancer, photodynamic diagnosis by anatomical location.
AUA 2024 SpaceOAR complications, MAUDE database, rectal wall infiltration, SpaceOAR Vue, Clavien-Dindo classification,
AUA 2024 intravesical chemotherapy in the management of BCG unresponsive non-muscle invasive bladder cancer, papillary versus CIS, patients with papillary-only tumors.
AUA 2024, Oligometastatic Prostate Cancer, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), Metastasis Directed Therapy (MDT), PSMA-PET Guided Metastasis Directed Therapy for Oligometastatic Prostate…
AUA 2024, prostate cancer, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), Temporal and Regional Patterns of Prostate Cancer Positron Emission Tomography Imaging, PET imaging,…
Phillip Koo hosts a discussion on patient selection for radioligand therapy (RLT) in prostate cancer, featuring Amir Iravani and Evan Yu. The conversation delves into…
AUA 2024 TAR-210, erdafitinib intravesical delivery system, non–muscle-invasive bladder cancer (NMIBC), Fibroblast Growth Factor Receptor (FGFR) alterations, pan-FGFR tyrosine kinase inhibitor.